Mindray Medical International (MR) Tops Q3 EPS by 1c; Guides FY12 EPS Growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Mindray Medical (MR) Growth Potential Offsets Negatives, Jefferies Reiterates Buy
November 7, 2012 1:56 PM ESTJefferies maintained a Buy rating on Mindray Medical (NYSE: MR) and raised its price target to $36.00 (from $34.00).
Commenting on the company's Q3 report, Jefferies analyst Raj Denhoy said, "MR put up a mixed 3Q with a drastic slowdown in PMLS, a sequential... More
